IRIS
FUMAROLA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.396
NA - Nord America 2.319
AS - Asia 1.132
AF - Africa 41
SA - Sud America 9
OC - Oceania 3
Totale 5.900
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.296
IT - Italia 642
CN - Cina 619
IE - Irlanda 443
FI - Finlandia 381
SE - Svezia 381
SG - Singapore 364
DE - Germania 178
UA - Ucraina 124
TR - Turchia 67
FR - Francia 52
GB - Regno Unito 49
IN - India 45
BE - Belgio 44
AT - Austria 39
CI - Costa d'Avorio 39
CA - Canada 23
CZ - Repubblica Ceca 18
NL - Olanda 14
HK - Hong Kong 12
VN - Vietnam 8
IR - Iran 7
PL - Polonia 6
AR - Argentina 4
BR - Brasile 4
ES - Italia 4
HU - Ungheria 4
JP - Giappone 4
CH - Svizzera 3
LU - Lussemburgo 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
RO - Romania 3
PK - Pakistan 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
EG - Egitto 1
HR - Croazia 1
JO - Giordania 1
KR - Corea 1
NO - Norvegia 1
PE - Perù 1
SI - Slovenia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 5.900
Salva come PNG Salva come JPEG
Città #
Dublin 443
Chandler 408
Ann Arbor 338
Singapore 279
Parma 204
Dearborn 155
Jacksonville 144
Boardman 122
Ashburn 106
Beijing 103
Shanghai 99
Nanjing 84
New York 70
Princeton 67
Izmir 65
Bremen 61
Milan 53
Helsinki 40
Nanchang 40
San Mateo 40
Abidjan 39
Vienna 38
Shenyang 37
Wilmington 34
Chicago 29
Los Angeles 29
Kunming 28
Hebei 27
Brussels 26
Modena 26
Hefei 25
Jinan 23
Marseille 23
Des Moines 22
Redmond 20
Seattle 18
Tianjin 17
Woodbridge 17
Munich 15
Pune 15
Norwalk 14
Santa Clara 14
Jiaxing 12
Neviano degli Arduini 12
Wayne 12
Changsha 11
Leawood 11
Toronto 11
Dallas 10
Fremont 10
Hong Kong 10
London 10
Amsterdam 9
Guangzhou 9
Bologna 8
Dong Ket 8
Fuzhou 8
Grafing 8
Verona 8
Ardabil 7
Augusta 7
Binche 7
Florence 7
Leuven 7
Reggio Emilia 7
Rome 7
Brno 6
Chengdu 6
Follonica 6
Frankfurt am Main 6
Manchester 6
Monmouth Junction 6
Montreal 6
Redwood City 6
Salsomaggiore Terme 6
Zhengzhou 6
Fairfield 5
Genoa 5
Ningbo 5
Casalgrande 4
Fidenza 4
Formigine 4
Gainesville 4
Haikou 4
Houston 4
Kolkata 4
Mons 4
Piacenza 4
Soliera 4
Taiyuan 4
Albano Laziale 3
Aveiro 3
Bari 3
Borås 3
Brescia 3
Buenos Aires 3
Castellarano 3
Coimbatore 3
Cuneo 3
Falls Church 3
Totale 3.822
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 208
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 126
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 125
Characterization of gefitinib uptake in NSCLC cell lines 114
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 112
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 107
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 105
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 104
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 104
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 103
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 100
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 98
Novel activity of a synthetic decapeptide against Toxoplasma gondii Tachyzoites 96
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 95
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 94
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 93
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 92
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 90
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 90
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 89
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 88
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 88
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 88
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 86
Physico-chemical characterization and biological evaluation of two fibroin materials 86
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 85
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 84
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 84
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 82
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 82
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 81
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 80
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 79
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 78
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 78
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 75
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 75
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 75
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 74
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 74
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 71
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 70
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 68
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 68
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 67
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 67
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 66
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 65
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 65
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 65
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 65
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 64
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 64
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 64
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 62
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 62
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 62
Increased level of inducible HSP70 in cells exposed to electromagnetic fields. 60
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 59
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 58
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 58
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 56
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 56
Synergistic activity of letrozole and sorafenib on breast cancer cells 55
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 55
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 53
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 53
Immunotherapeutic approaches in malignant pleural mesothelioma 52
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 52
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 51
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer 50
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 48
New therapeutic strategies for malignant pleural mesothelioma 47
Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 46
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 45
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 45
Targeting FGFR1 pathway in squamous cell lung cancer 44
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 33
null 31
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 24
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 14
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 13
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 11
Effect of constitutive expression of the fragile histidine triad gene on non small cell lung cancer 11
Totale 6.062
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.530
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.530
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020651 0 0 0 0 67 127 159 42 94 68 38 56
2020/2021552 13 49 38 37 59 16 48 30 86 23 113 40
2021/2022418 36 15 21 38 15 10 70 30 21 19 30 113
2022/20231.723 147 183 121 118 159 196 14 142 540 9 73 21
2023/2024812 38 51 29 43 55 157 68 72 33 45 89 132
2024/2025701 87 112 169 179 154 0 0 0 0 0 0 0
Totale 6.062